ArticleStem cell research & therapy2026
iPSC-derived cardiac organoids for drug cardiotoxicity evaluation and efficacy prediction in myocardial infarction and cardiac hypertrophy models.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac organoids (COs) derived from induced pluripotent stem cells (iPSCs) constitute a three-dimensional microphysiological system that more faithfully recapitulates the structural and functional complexity of human heart tissues compared to traditional two-dimensional cultures or animal models. Therefore, it highlights the significance of iPSC-derived COs in providing more precise platform for assessing drug cytotoxicity, cardiac functional toxicity, developmental toxicity, and therapeutic efficacy in disease models.
methodsHuman iPSCs, after generation from somatic cells using reprogramming factors, were differentiated into COs using dynamic culture system. COs were characterized by cell composition, structure, spontaneous beating, electrophysiological properties. Furthermore, drug cytotoxicity was evaluated by assessing cell viability and lactate dehydrogenase release after exposure of COs to doxorubicin. Cardiac functional toxicity was assessed by monitoring changes in beating after exposure to different compounds. In addition, developmental toxicity was tested using thalidomide. Finally, cardioprotective drug efficacy was evaluated based on the construction of myocardial infarction (MI) and cardiac hypertrophy (CH) models.
resultsThe reprogrammed iPSCs have successfully generated COs with complex structure and function. Myocardial toxicity induced by anthracycline drugs was faithfully reproduced in organoids. This work also examined the effects of isoproterenol, MYK461, E-4031, and nifedipine on cardiac beating. Long-term exposure to thalidomide triggered abnormal atrial-ventricular differentiation in COs. In MI model, cyclosporine A exerted cardioprotective effects by downregulating apoptosis and inflammation. In CH model, on the other hand, apocynin outperformed metoprolol in alleviating Ang II-induced cardiac hypertrophy.
conclusionsThis study establishes an efficient and stable method for generating uniform and functionally mature COs by utilising dynamic culture systems. Also, we proposes a reliable approach for drug-induced cardiotoxicity assessment and efficacy evaluation on the organoid platform, offering a multipurpose and cutting-edge tool for cardiac drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.